# Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

> **NCT02168491** · PHASE3 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 10 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Lixisenatide
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT02168491
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168491, "Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02168491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*